Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to identify a safe dose of MK-2248 in participants with
Hepatitis C Virus (HCV) that mediates at least a 3 log10 reduction in viral load (VL) from
baseline. It is anticipated that once-daily administration of a safe and well tolerated dose
of MK-2248 will reduce VL by at least 3 log10 IU/mL.